Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.…
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
Agios Pharmaceuticals (NASDAQ: AGIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 539 employees.
The shares were at 27.60 USD on 20 November 2026, down 31.9% over 52 weeks. Its 52-week range is 22.24 USD to 46.00 USD: the price is 40.0% below the high and 24.1% above the low.
Its market capitalisation is 1.65B USD.
Agios Pharmaceuticals reports return on equity of -34.6%, an operating margin of -297.7% and revenue up 330.0% year over year.
It holds more cash than debt, a net cash position of 603.48M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 46.11 USD is 67.1% above the current price. The next earnings report is expected on 18 February 2027.